ADMA Biologics, Inc.

NasdaqGM:ADMA Rapport sur les actions

Capitalisation boursière : US$4.2b

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

ADMA Biologics Gestion

Gestion contrôle des critères 3/4

Le PDG ADMA Biologics' est Adam Grossman, nommé en Jan2007, a un mandat de 17.58 ans. La rémunération annuelle totale est $ 6.04M, composée du salaire de 12.4% et des bonus 87.6%, y compris les actions et options de la société. détient directement 1.07% des actions de la société, d'une valeur de $ 43.64M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 0.6 ans et 12.1 ans.

Informations clés

Adam Grossman

Directeur général

US$6.0m

Rémunération totale

Pourcentage du salaire du PDG12.4%
Durée du mandat du directeur général17.6yrs
Propriété du PDG1.1%
Durée moyenne d'occupation des postes de directionless than a year
Durée moyenne du mandat des membres du conseil d'administration12.1yrs

Mises à jour récentes de la gestion

Recent updates

ADMA Biologics' (NASDAQ:ADMA) Strong Earnings Are Of Good Quality

Aug 16
ADMA Biologics' (NASDAQ:ADMA) Strong Earnings Are Of Good Quality

ADMA Biologics: A Compelling GARP Stock For Biotech Investors

Jul 27

ADMA Biologics, Inc. (NASDAQ:ADMA) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Jul 24
ADMA Biologics, Inc. (NASDAQ:ADMA) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Is ADMA Biologics (NASDAQ:ADMA) Using Too Much Debt?

Jul 17
Is ADMA Biologics (NASDAQ:ADMA) Using Too Much Debt?

Is ADMA Biologics, Inc. (NASDAQ:ADMA) Trading At A 43% Discount?

May 30
Is ADMA Biologics, Inc. (NASDAQ:ADMA) Trading At A 43% Discount?

ADMA Biologics, Inc. Just Beat EPS By 45%: Here's What Analysts Think Will Happen Next

May 13
ADMA Biologics, Inc. Just Beat EPS By 45%: Here's What Analysts Think Will Happen Next

Giving ADMA Biologics A Well-Deserved 'Booyah'

May 12

ADMA Biologics, Inc.'s (NASDAQ:ADMA) Prospects Need A Boost To Lift Shares

May 08
ADMA Biologics, Inc.'s (NASDAQ:ADMA) Prospects Need A Boost To Lift Shares

Is ADMA Biologics (NASDAQ:ADMA) A Risky Investment?

Apr 04
Is ADMA Biologics (NASDAQ:ADMA) A Risky Investment?

Rising Margins And Product Promise Drive ADMA Biologics Forward (Rating Upgrade)

Apr 03

ADMA Biologics: On A Roll Entering 2024

Jan 19

Is There An Opportunity With ADMA Biologics, Inc.'s (NASDAQ:ADMA) 50% Undervaluation?

Jan 09
Is There An Opportunity With ADMA Biologics, Inc.'s (NASDAQ:ADMA) 50% Undervaluation?

ADMA Biologics, Inc. (NASDAQ:ADMA) Surges 30% Yet Its Low P/S Is No Reason For Excitement

Jan 09
ADMA Biologics, Inc. (NASDAQ:ADMA) Surges 30% Yet Its Low P/S Is No Reason For Excitement

We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt

Oct 25
We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt

We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt

Jun 10
We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt

The Market Doesn't Like What It Sees From ADMA Biologics, Inc.'s (NASDAQ:ADMA) Revenues Yet

May 12
The Market Doesn't Like What It Sees From ADMA Biologics, Inc.'s (NASDAQ:ADMA) Revenues Yet

ADMA Biologics: Strong Growth Is Clearing The Path To Profitability

Aug 21

ADMA Biologics GAAP EPS of -$0.07, revenue of $33.9M

Aug 10

ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt

Jun 01
ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt

ADMA Biologics: A Path To Profits Looks Clear

May 12

ADMA: Pertinent Updates

Apr 18

ADMA Biologics' 2021 Numbers Showed Continued Strong Execution

Mar 29

ADMA Biologics: 2021 Was Tough

Jan 18

ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt

Dec 02
ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt

ADMA Biologics: Turning A Corner

Nov 20

ADMA: Insiders Showing Their Cards

Nov 02

ADMA Biologics: Recent Significant Developments And Their Implications For The Stock

Aug 22

Analyse de la rémunération des PDG

Comment la rémunération de Adam Grossman a-t-elle évolué par rapport aux bénéfices de ADMA Biologics?
DateRémunération totaleSalaireBénéfices de l'entreprise
Jun 30 2024n/an/a

US$35m

Mar 31 2024n/an/a

-US$4m

Dec 31 2023US$6mUS$750k

-US$28m

Sep 30 2023n/an/a

-US$23m

Jun 30 2023n/an/a

-US$40m

Mar 31 2023n/an/a

-US$48m

Dec 31 2022US$3mUS$637k

-US$66m

Sep 30 2022n/an/a

-US$70m

Jun 30 2022n/an/a

-US$73m

Mar 31 2022n/an/a

-US$78m

Dec 31 2021US$4mUS$618k

-US$72m

Sep 30 2021n/an/a

-US$74m

Jun 30 2021n/an/a

-US$74m

Mar 31 2021n/an/a

-US$75m

Dec 31 2020US$2mUS$600k

-US$76m

Sep 30 2020n/an/a

-US$67m

Jun 30 2020n/an/a

-US$61m

Mar 31 2020n/an/a

-US$54m

Dec 31 2019US$2mUS$536k

-US$48m

Sep 30 2019n/an/a

-US$56m

Jun 30 2019n/an/a

-US$59m

Mar 31 2019n/an/a

-US$61m

Dec 31 2018US$2mUS$536k

-US$66m

Sep 30 2018n/an/a

-US$61m

Jun 30 2018n/an/a

-US$61m

Mar 31 2018n/an/a

-US$55m

Dec 31 2017US$3mUS$494k

-US$44m

Rémunération vs marché: La rémunération totale de Adam ($USD 6.04M ) est dans la moyenne des entreprises de taille similaire sur le marché US ($USD 6.76M ).

Rémunération et revenus: La rémunération de Adam a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.


PDG

Adam Grossman (47 yo)

17.6yrs

Titularisation

US$6,039,649

Compensation

Mr. Adam S. Grossman serves as Director at BioFlorida Inc since August 2021. He is the Co-Founder of ADMA Biologics, Inc. and has been its Chief Executive Officer and President since October 2011 and 2007...


Équipe de direction

NomPositionTitularisationCompensationPropriété
Adam Grossman
Co-Founder17.6yrsUS$6.04m1.07%
$ 45.3m
Jerrold Grossman
Co-Founder & Vice Chairman of the Board17.6yrsUS$284.72k0.21%
$ 9.1m
Brad Tade
CFO & Treasurerless than a yearpas de données0.092%
$ 3.9m
Kaitlin Kestenberg
COO & Senior VP of Complianceless than a yearpas de données0.054%
$ 2.3m
Drew Pantello
Vice President of Marketing & Corporate Developmentno datapas de donnéespas de données
John Hafl
Executive Director of Salesless than a yearpas de donnéespas de données
Cindy Petersen
Executive Director of Human Resources2.6yrspas de donnéespas de données
Skyler Bloom
Senior Director of Business Development & Corporate Strategyno datapas de donnéespas de données

0.6yrs

Durée moyenne de l'emploi

49yo

Âge moyen

Gestion expérimentée: L'équipe de direction de ADMA n'est pas considérée comme expérimentée (ancienneté moyenne 0.6 ans), ce qui suggère une nouvelle équipe.


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Adam Grossman
Co-Founder17.6yrsUS$6.04m1.07%
$ 45.3m
Jerrold Grossman
Co-Founder & Vice Chairman of the Board17.6yrsUS$284.72k0.21%
$ 9.1m
Bryant Fong
Independent Director12.3yrsUS$280.72k0.026%
$ 1.1m
Steven Elms
Independent Chairman17.6yrsUS$290.22k0.022%
$ 954.7k
Young Kwon
Independent Director2.8yrsUS$272.34k0.12%
$ 5.1m
Michael Green
Member of Scientific Advisory Boardno datapas de donnéespas de données
Lawrence Guiheen
Independent Director12.1yrsUS$275.09k0.056%
$ 2.4m
Roy Chemaly
Member of Scientific Advisory Board10.2yrspas de donnéespas de données
Jordan Orange
Member of Scientific Advisory Board10.2yrspas de donnéespas de données
Alison Finger
Independent Directorless than a yearUS$231.12kpas de données
Jean-Laurent Casanova
Member of Scientific Advisory Boardno datapas de donnéespas de données
Ann Falsey
Member of Scientific Advisory Boardno datapas de donnéespas de données

12.1yrs

Durée moyenne de l'emploi

59yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration ADMA sont chevronnés et expérimentés (durée moyenne d'administration 12.1 ans).